Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
about
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesCUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseasesImmunotherapy strategies for multiple myeloma: the present and the futurep38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.Antibody-based therapeutics for the treatment of human B cell malignanciesImmunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Dendritic Cell Therapies for Hematologic Malignancies.Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.Mouse models of multiple myeloma: technologic platforms and perspectives.
P2860
Q26864603-ECB023FD-E7AD-4721-AEFB-F753C86A8BF9Q26999045-08480869-C8E1-49CA-B120-369FA9F7CBFDQ27021939-DB5494BC-D9D7-455F-B4BB-B4B171AAAB64Q30422500-04C6A168-1FF2-432E-944A-ADD11444C6C7Q33721123-914C6596-B957-4219-AA3B-5B31C90F6F32Q34052565-BA017F58-AD20-4789-8B56-B4E8F58BDA3DQ36278425-939C3095-60F2-425A-8D6D-4F34A417A70AQ36907540-843100B7-717D-4F82-916D-12982E207A7CQ37693346-39823C68-E902-4547-B399-3EC505A430F2Q38815399-6DB5A31F-31EA-4CBB-A843-0054A208B30BQ39289930-A2A045C9-7A67-427C-AEB9-EFFBAB1089B4Q40674036-2C0BF4A4-CABE-41B1-8603-BDC22DD1F9D0Q54941353-CFD50AB2-5620-46B0-A932-B6460F5522D0Q55038802-D6A4F19B-843E-4A15-AE27-38D0B7603F37
P2860
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@en
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@nl
type
label
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@en
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@nl
prefLabel
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@en
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@nl
P2093
P2860
P1476
Optimizing dendritic cell vacc ...... promote anti-tumour immunity.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.2012.04642.X
P577
2012-11-01T00:00:00Z